Recent advances in nanotechnology have enabled significant developments in health through innovative drug delivery systems. Nanostructured lipid carriers (NLCs) have emerged as a key technology in this field, offering enhanced drug stability, improved loading capacity, and reduced drug leakage compared to traditional solid lipid nanoparticles (SLNs). NLCs, such as ARM-NLC and PIO-loaded NLCs are specifically designed to optimize drug delivery and efficacy. Unlike other nanocarriers, NLCs provide controlled release and targeted delivery, making them highly effective for treating a range of diseases. Their applications include the treatment of skin cancer, Parkinson's disease, Alzheimer's disease, and breast cancer. The use of surface-engineered nanolayer coatings in NLCs has demonstrated significant improvements in targeting and delivering medications and bioactive substances to infection sites. Both in vitro and in vivo studies have shown promising results regarding the safety and efficacy of these NLC-based drug delivery systems.

The present investigation on nanoliposome infused with oxymetazoline hydrochloride was fabricated with phosphatidylcholine and cholesterol to effectively deliver the drug to the skin. Oxymetazoline hydrochloride evidence to show anti-inflammatory characteristics. The drug produces pro-resolving lipoxins in accordance with the formation of anti-inflammatory 15(S)-hydroxy-eicosatetraenoic acid and the consequent reduction of proinflammatory lipid mediators such as leukotriene B4 which leads to the reduction in inflammation at the topical region. The oxymetazoline hydrochloride infused nanoliposomes were prepared by thin film lipid hydration method. The present research assessed the average particle size of different formulations ranges from 147.4±0.77 nm to 371.7±0.99 nm with polydispersity value ranging from 0.181±0.02 to 0.392±0.03. Furthermore, the zeta potentials ranging from -15.2±0.25 mV to -30.5±0.24 mV. The percentage of drug release at 12 h (Y1) has a p-value of 0.0073, entrapment efficiency (%) (Y2) has p-value of 0.0001 and particle size (nm) (Y3) has a p-value of 0.0480. Hence all the dependent responses found to be significant. This study exhibited small particle size distribution with consistent polydispersity index which ensure the monodispersed nature of the nanoliposomes. The satisfactory zeta potential value indicates the stability of formulation. The outcome of the study projected that oxymetazoline hydrochloride loaded nanoliposome have the potential to deliver drugs to specific regions with their high stability and predictable release at the target region.

Alkaloids, naturally occurring compounds in a diverse range of plant species (Coffea spp., Erythroxylum coca, Cinchona spp. etc.), hold vast potential for biological, medicinal, and pharmacological applications. As the global focus shifts towards natural therapeutic agents due to their lower toxicity compared to synthetic compounds, this review takes a novel approach by examining the ecological and molecular factors influencing the medicinal properties of alkaloids. Using a comparative analysis of alkaloid potency across various plant species, we explore how environmental factors, such as soil composition and climate, impact alkaloid concentration and efficacy. Additionally, this review highlights the synergistic potential of alkaloids when combined with other phytochemicals, offering new insights into more potent, multi-compound therapeutic formulations. We documented ten key medicinal properties, including antioxidant, anti-inflammatory, and anticancer effects, and delve into the molecular pathways through which alkaloids exert these benefits. By exploring alkaloids from under-researched plant species, we aim to broaden the scope of medicinal applications, particularly within the realm of personalized medicine, where alkaloid efficacy may vary based on genetic and pathological factors. This novel perspective emphasized the need for further research to optimize alkaloid extraction methods and assess their potential in personalized and combination therapies, ultimately paving the way for more effective natural treatments.

Transdermal Drug Delivery Systems (TDDSs) provide controlled and prolonged drug release, enhance patient compliance, reduce gastrointestinal side effects, and improve drug stability. By delivering medication directly through the skin, TDDSs avoid the initial breakdown of the drug in the liver, which can enhance the amount of medication that reaches the bloodstream. The noninvasive nature of TDDSs reduces discomfort for patients by eliminating the need for invasive procedures like injections, enabling uninterrupted use throughout the day. Innovations such as the development of microneedles with adjustable depths and nanoparticles with targeted drug delivery capabilities have significantly improved the accuracy and efficiency of TDDSs. TDDSs have potential applications beyond pain management, including treating chronic conditions such as diabetes and hypertension.

Background: The objective of this article is to examine the challenges and best strategies for incorporating data integrity in the pharmaceutical industry to ensure regulatory compliance. It highlights the importance of data governance policies, secure data handling processes, and the use of the ALCOA framework for implementing Good Documentation Practices.

Evidence acquisition: Using appropriate search terms such as ‘Data Integrity', ‘Data Integrity in Pharmaceutical Industry', and ‘ALCOA principle', evidence was gathered from websites and published articles using SciFinder, Web of Science, PubMed, UGC-approved journals, and Google Scholar databases.

Results: The article emphasizes the importance of change management, independent data review methods, and modern technology such as electronic signatures and audit trails in pharmaceutical companies. It also points out the importance of data backup, recovery procedures, and ongoing improvement in maintaining data integrity and promoting responsibility.

Conclusion: The article discusses the pharmaceutical sector's procedures for ensuring data integrity throughout a product's life, promoting safe, efficient, and excellent pharmaceutical goods. It highlights the need to navigate the complex regulatory environment and emphasizes the sector's commitment to maintaining data integrity to achieve high quality standards in manufacturing and testing operations.

This paper proposes an innovative method for visualizing pain by transforming complex pain metrics into intuitive visual codes, making pain expression more precise and easier to understand and empathize with. The system categorizes pain by type, source, intensity, and range, employing creative visual elements to vividly represent these categories. This design not only enhances the clarity and accuracy of pain communication but also bridges the gap between patient experience and medical interpretation, providing a more human-centered solution in the healthcare field.